Verastem Oncology, Inc. (NASDAQ: VSTM) is a biopharmaceutical company headquartered in Needham, Massachusetts. The company is developing a portfolio of novel small molecule kinase inhibitors targeting malignant cells both directly and through modulation of the tumor microenvironment.
Verastem is a member of NASDAQ Biotechnology Index.
Our pipeline focuses on a portfolio of novel small molecule drugs inhibiting critical signaling pathways in cancer. Clinical product candidates, phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and RAF/MEK inhibitors, are currently being evaluated in multiple clinical collaborations for the treatment of several different tumors.